NCT05672316View on ClinicalTrials.gov

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

October 27, 2025

Study Completion Date

October 27, 2025

Conditions
Advanced Colorectal AdenocarcinomaAdvanced Microsatellite Stable Colorectal CarcinomaMetastatic Colorectal AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaStage III Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8
Interventions
BIOLOGICAL

Balstilimab

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood

BIOLOGICAL

Botensilimab

Given IV

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Regorafenib

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER